Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 723

1.

Current and Emerging Biologics for the Treatment of Neuromyelitis Optica Spectrum Disorders.

Duchow A, Paul F, Bellmann-Strobl J.

Expert Opin Biol Ther. 2020 Mar 31. doi: 10.1080/14712598.2020.1749259. [Epub ahead of print]

PMID:
32228250
2.

Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey.

D'Souza M, Papadopoulou A, Levy M, Jacob A, Yeaman MR, Kümpfel T, Marignier R, Paul F, Brandt AU.

Mult Scler Relat Disord. 2020 Feb 29;41:102027. doi: 10.1016/j.msard.2020.102027. [Epub ahead of print]

PMID:
32179483
3.

Dysphagia Affecting Quality of Life in Cerebellar Ataxia-a Large Survey.

Rönnefarth M, Hanisch N, Brandt AU, Mähler A, Endres M, Paul F, Doss S.

Cerebellum. 2020 Mar 13. doi: 10.1007/s12311-020-01122-w. [Epub ahead of print]

PMID:
32170655
4.

Vitamin D and Disease Severity in Multiple Sclerosis-Baseline Data From the Randomized Controlled Trial (EVIDIMS).

Bäcker-Koduah P, Bellmann-Strobl J, Scheel M, Wuerfel J, Wernecke KD, Dörr J, Brandt AU, Paul F.

Front Neurol. 2020 Feb 25;11:129. doi: 10.3389/fneur.2020.00129. eCollection 2020.

5.

Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina.

Faissner S, Graz F, Reinehr S, Petrikowski L, Haupeltshofer S, Ceylan U, Stute G, Winklmeier S, Pache F, Paul F, Ruprecht K, Meinl E, Dick HB, Gold R, Kleiter I, Joachim SC.

J Neuroimmunol. 2020 Feb 20;342:577194. doi: 10.1016/j.jneuroim.2020.577194. [Epub ahead of print]

PMID:
32143071
6.

Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.

Cellerino M, Ivaldi F, Pardini M, Rotta G, Vila G, Bäcker-Koduah P, Berge T, Laroni A, Lapucci C, Novi G, Boffa G, Sbragia E, Palmeri S, Asseyer S, Høgestøl E, Campi C, Piana M, Inglese M, Paul F, Harbo HF, Villoslada P, Kerlero de Rosbo N, Uccelli A.

Neurol Neuroimmunol Neuroinflamm. 2020 Mar 5;7(3). pii: e693. doi: 10.1212/NXI.0000000000000693. Print 2020 May.

7.

Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.

Albert C, Mikolajczak J, Liekfeld A, Piper SK, Scheel M, Zimmermann HG, Nowak C, Dörr J, Bellmann-Strobl J, Chien C, Brandt AU, Paul F, Hoffmann O.

BMC Neurol. 2020 Mar 3;20(1):75. doi: 10.1186/s12883-020-01645-z.

8.

Cortical topological network changes following optic neuritis.

Backner Y, Ben-Shalom I, Kuchling J, Siebert N, Scheel M, Ruprecht K, Brandt A, Paul F, Levin N.

Neurol Neuroimmunol Neuroinflamm. 2020 Mar 2;7(3). pii: e687. doi: 10.1212/NXI.0000000000000687. Print 2020 May.

9.

Triarylisocyanurate-Based Fluorescent Two-Photon Absorbers.

Gautier Y, Argouarch G, Malvolti F, Blondeau B, Richy N, Amar A, Boucekkine A, Nawara K, Chlebowicz K, Orzanowska G, Dudek M, Matczyszyn K, Samoc M, Blanchard-Desce M, Mongin O, Waluk J, Paul F.

Chempluschem. 2020 Mar;85(3):411-425. doi: 10.1002/cplu.202000036.

PMID:
32119196
10.

Synthesis, characterization and unusual near-infrared luminescence of 1,1,4,4-tetracyanobutadiene derivatives.

Bui AT, Philippe C, Beau M, Richy N, Cordier M, Roisnel T, Lemiègre L, Mongin O, Paul F, Trolez Y.

Chem Commun (Camb). 2020 Mar 24;56(24):3571-3574. doi: 10.1039/c9cc09560h.

PMID:
32104794
11.

Prodromal headache in MOG-antibody positive optic neuritis.

Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, Küker W, Bellmann-Strobl J, Ruprecht K, Jarius S, Leite MI, U Brandt A, Paul F, Palace J.

Mult Scler Relat Disord. 2020 Jan 25;40:101965. doi: 10.1016/j.msard.2020.101965. [Epub ahead of print]

PMID:
32062443
12.

High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial.

Dörr J, Bäcker-Koduah P, Wernecke KD, Becker E, Hoffmann F, Faiss J, Brockmeier B, Hoffmann O, Anvari K, Wuerfel J, Piper SK, Bellmann-Strobl J, Brandt AU, Paul F.

Mult Scler J Exp Transl Clin. 2020 Jan 24;6(1):2055217320903474. doi: 10.1177/2055217320903474. eCollection 2020 Jan-Mar.

13.

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning.

Arloth J, Eraslan G, Andlauer TFM, Martins J, Iurato S, Kühnel B, Waldenberger M, Frank J, Gold R, Hemmer B, Luessi F, Nischwitz S, Paul F, Wiendl H, Gieger C, Heilmann-Heimbach S, Kacprowski T, Laudes M, Meitinger T, Peters A, Rawal R, Strauch K, Lucae S, Müller-Myhsok B, Rietschel M, Theis FJ, Binder EB, Mueller NS.

PLoS Comput Biol. 2020 Feb 3;16(2):e1007616. doi: 10.1371/journal.pcbi.1007616. eCollection 2020 Feb.

14.

Identification of Druggable Kinase Target Conformations Using Markov Model Metastable States Analysis of apo-Abl.

Paul F, Meng Y, Roux B.

J Chem Theory Comput. 2020 Mar 10;16(3):1896-1912. doi: 10.1021/acs.jctc.9b01158. Epub 2020 Feb 13.

PMID:
31999924
15.

Gas-containing renal stones.

Peter J, Bhat S, Paul F.

Indian J Urol. 2020 Jan-Mar;36(1):67-68. doi: 10.4103/iju.IJU_271_19.

16.

Considerations for Mean Upper Cervical Cord Area Implementation in a Longitudinal MRI Setting: Methods, Interrater Reliability, and MRI Quality Control.

Chien C, Juenger V, Scheel M, Brandt AU, Paul F.

AJNR Am J Neuroradiol. 2020 Feb;41(2):343-350. doi: 10.3174/ajnr.A6394. Epub 2020 Jan 23.

PMID:
31974079
17.

Antibody signatures in patients with histopathologically defined multiple sclerosis patterns.

Stork L, Ellenberger D, Ruprecht K, Reindl M, Beißbarth T, Friede T, Kümpfel T, Gerdes LA, Gloth M, Liman T, Paul F, Brück W, Metz I.

Acta Neuropathol. 2020 Mar;139(3):547-564. doi: 10.1007/s00401-019-02120-x. Epub 2020 Jan 16.

18.

Phthalocyanine-Cored Fluorophores with Fluorene-Containing Peripheral Two-Photon Antennae as Photosensitizers for Singlet Oxygen Generation.

Abid S, Hassine SB, Richy N, Camerel F, Jamoussi B, Blanchard-Desce M, Mongin O, Paul F, Paul-Roth CO.

Molecules. 2020 Jan 7;25(2). pii: E239. doi: 10.3390/molecules25020239.

19.

Author Correction: Global glacier mass changes and their contributions to sea-level rise from 1961 to 2016.

Zemp M, Huss M, Thibert E, Eckert N, McNabb R, Huber J, Barandun M, Machguth H, Nussbaumer SU, Gärtner-Roer I, Thomson L, Paul F, Maussion F, Kutuzov S, Cogley JG.

Nature. 2020 Jan;577(7792):E9. doi: 10.1038/s41586-019-1889-5.

PMID:
31925404
20.

Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study.

Bahr LS, Bock M, Liebscher D, Bellmann-Strobl J, Franz L, Prüß A, Schumann D, Piper SK, Kessler CS, Steckhan N, Michalsen A, Paul F, Mähler A.

Trials. 2020 Jan 2;21(1):3. doi: 10.1186/s13063-019-3928-9.

21.

Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis.

Böttcher C, Fernández-Zapata C, Schlickeiser S, Kunkel D, Schulz AR, Mei HE, Weidinger C, Gieß RM, Asseyer S, Siegmund B, Paul F, Ruprecht K, Priller J.

Sci Rep. 2019 Dec 19;9(1):19471. doi: 10.1038/s41598-019-55852-x.

22.

Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

Ostendorf L, Mothes R, van Koppen S, Lindquist RL, Bellmann-Strobl J, Asseyer S, Ruprecht K, Alexander T, Niesner RA, Hauser AE, Paul F, Radbruch H.

Front Immunol. 2019 Nov 29;10:2725. doi: 10.3389/fimmu.2019.02725. eCollection 2019.

23.

Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials.

Gehr S, Kaiser T, Kreutz R, Ludwig WD, Paul F.

EPMA J. 2019 Nov 22;10(4):425-436. doi: 10.1007/s13167-019-00192-z. eCollection 2019 Dec. Review.

24.

N2 year in review.

Dalmau J, Dalakas MC, Kolson DL, Paul F, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2019 Dec 12;7(1). pii: e644. doi: 10.1212/NXI.0000000000000644. Print 2020 Jan. No abstract available.

25.

Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline.

Motamedi S, Gawlik K, Ayadi N, Zimmermann HG, Asseyer S, Bereuter C, Mikolajczak J, Paul F, Kadas EM, Brandt AU.

Front Neurol. 2019 Nov 25;10:1117. doi: 10.3389/fneur.2019.01117. eCollection 2019.

26.

Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.

Ringelstein M, Harmel J, Zimmermann H, Brandt AU, Paul F, Haarmann A, Buttmann M, Hümmert MW, Trebst C, Schroeder C, Ayzenberg I, Kleiter I, Hellwig K, Havla J, Kümpfel T, Jarius S, Wildemann B, Rommer P, Weber MS, Pellkofer H, Röpke L, Geis C, Retzlaff N, Zettl U, Deppe M, Klotz L, Young K, Stellmann JP, Kaste M, Kermer P, Marouf W, Lauda F, Tumani H, Graf J, Klistorner A, Hartung HP, Aktas O, Albrecht P; Neuromyelitis Optica Study Group (NEMOS).

Neurology. 2020 Jan 28;94(4):e407-e418. doi: 10.1212/WNL.0000000000008684. Epub 2019 Dec 3.

PMID:
31796527
27.

Contactless recording of sleep apnea and periodic leg movements by nocturnal 3-D-video and subsequent visual perceptive computing.

Veauthier C, Ryczewski J, Mansow-Model S, Otte K, Kayser B, Glos M, Schöbel C, Paul F, Brandt AU, Penzel T.

Sci Rep. 2019 Nov 14;9(1):16812. doi: 10.1038/s41598-019-53050-3.

28.

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M.

Bone Marrow Transplant. 2020 Apr;55(4):729-739. doi: 10.1038/s41409-019-0720-0. Epub 2019 Oct 23.

PMID:
31645668
29.

Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation.

Eitel F, Soehler E, Bellmann-Strobl J, Brandt AU, Ruprecht K, Giess RM, Kuchling J, Asseyer S, Weygandt M, Haynes JD, Scheel M, Paul F, Ritter K.

Neuroimage Clin. 2019;24:102003. doi: 10.1016/j.nicl.2019.102003. Epub 2019 Sep 6.

30.

Age-related schwannomatosis with potential exosome-mediated contribution to prostate hyperplasia: a case report and mini-review.

Chignon-Sicard B, Hofman V, Chevallier D, Cucchi JM, Ilié M, Dadone-Montaudié B, Paul F, Carpentier X, Quintens H, Bence-Gauchiez C, Caselles D, Rossant J, Durand M, Bertolotti R.

Ther Adv Urol. 2019 Sep 26;11:1756287219875578. doi: 10.1177/1756287219875578. eCollection 2019 Jan-Dec.

31.

Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.

Knöfler R, Lange BS, Paul F, Tiebel O, Suttorp M.

Br J Haematol. 2020 Mar;188(5):701-706. doi: 10.1111/bjh.16241. Epub 2019 Oct 15.

PMID:
31617211
32.

Biocompatible conjugated fluorenylporphyrins for two-photon photodynamic therapy and fluorescence imaging.

Shi L, Nguyen C, Daurat M, Dhieb AC, Smirani W, Blanchard-Desce M, Gary-Bobo M, Mongin O, Paul-Roth C, Paul F.

Chem Commun (Camb). 2019 Oct 8;55(81):12231-12234. doi: 10.1039/c9cc05657b.

PMID:
31553001
33.

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study.

Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium.

Mult Scler J Exp Transl Clin. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep.

34.

Brain iron and metabolic abnormalities in C19orf12 mutation carriers: A 7.0 tesla MRI study in mitochondrial membrane protein-associated neurodegeneration.

Dusek P, Mekle R, Skowronska M, Acosta-Cabronero J, Huelnhagen T, Robinson SD, Schubert F, Deschauer M, Els A, Ittermann B, Schottmann G, Madai VI, Paul F, Klopstock T, Kmiec T, Niendorf T, Wuerfel J, Schneider SA.

Mov Disord. 2020 Jan;35(1):142-150. doi: 10.1002/mds.27827. Epub 2019 Sep 13.

PMID:
31518459
35.

Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.

Pfuhl C, Grittner U, Gieß RM, Scheel M, Behrens JR, Rasche L, Pache FC, Wenzel R, Brandt AU, Bellmann-Strobl J, Paul F, Ruprecht K, Oechtering J.

Neurology. 2019 Oct 8;93(15):e1439-e1451. doi: 10.1212/WNL.0000000000008237. Epub 2019 Sep 9.

PMID:
31501228
36.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.

PMID:
31495497
37.

Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.

Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Kappos L, Montalban X, Rovira À, Evangelou N, Wuerfel J; MAGNIMS Study Group.

JAMA Neurol. 2019 Aug 19. doi: 10.1001/jamaneurol.2019.2478. [Epub ahead of print]

PMID:
31424490
38.

Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?

Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, Lotan I.

Neurol Neuroimmunol Neuroinflamm. 2019 May 21;6(4):e572. doi: 10.1212/NXI.0000000000000572. eCollection 2019 Jul.

39.

Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study.

Oertel FC, Outteryck O, Knier B, Zimmermann H, Borisow N, Bellmann-Strobl J, Blaschek A, Jarius S, Reindl M, Ruprecht K, Meinl E, Hohlfeld R, Paul F, Brandt AU, Kümpfel T, Havla J.

J Neuroinflammation. 2019 Jul 25;16(1):154. doi: 10.1186/s12974-019-1521-5.

40.

Fluorenylporphyrins functionalized by electrochromic ruthenium units as redox-triggered fluorescence switches.

Zhang X, Abid S, Shi L, Williams JAG, Fox MA, Miomandre F, Tourbillon C, Audibert JF, Mongin O, Paul F, Paul-Roth CO.

Dalton Trans. 2019 Aug 21;48(31):11897-11911. doi: 10.1039/c9dt02087j. Epub 2019 Jul 16.

41.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Dec;90(12):1245-1253. doi: 10.1007/s00115-019-0760-0. Review. German.

PMID:
31297574
42.

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group.

Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.

PMID:
31278067
43.

Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders.

Gkaniatsou T, Papadopoulou A, Paul F, Brandt AU, Oertel FC.

Acta Neurol Belg. 2020 Feb;120(1):223-225. doi: 10.1007/s13760-019-01176-6. Epub 2019 Jul 1. No abstract available.

PMID:
31264181
44.

Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features.

Oertel FC, Schließeit J, Brandt AU, Paul F.

Front Neurol. 2019 Jun 12;10:608. doi: 10.3389/fneur.2019.00608. eCollection 2019. Review.

45.

Canine Brucellosis: Insights Into the Epidemiologic Situation in Europe.

Buhmann G, Paul F, Herbst W, Melzer F, Wolf G, Hartmann K, Fischer A.

Front Vet Sci. 2019 May 31;6:151. doi: 10.3389/fvets.2019.00151. eCollection 2019.

46.

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA.

Brain. 2019 Jul 1;142(7):1858-1875. doi: 10.1093/brain/awz144.

47.

Neural mechanisms of perceptual decision-making and their link to neuropsychiatric symptoms in multiple sclerosis.

Weygandt M, Behrens J, Brasanac J, Söder E, Meyer-Arndt L, Wakonig K, Ritter K, Brandt AU, Bellmann-Strobl J, Gold SM, Haynes JD, Paul F.

Mult Scler Relat Disord. 2019 Aug;33:139-145. doi: 10.1016/j.msard.2019.05.025. Epub 2019 May 30.

PMID:
31195338
48.

Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.

Klehmet J, Beutner S, Hoffmann S, Dornauer M, Paul F, Reilmann R, Brandt AU, Meisel A.

BMC Neurol. 2019 Jun 8;19(1):118. doi: 10.1186/s12883-019-1339-x.

49.

Olfactory and Gustatory Dysfunction in Patients With Autoimmune Encephalitis.

Geran R, Uecker FC, Prüss H, Haeusler KG, Paul F, Ruprecht K, Harms L, Schmidt FA.

Front Neurol. 2019 May 14;10:480. doi: 10.3389/fneur.2019.00480. eCollection 2019.

50.

Vision and Vision-Related Measures in Progressive Multiple Sclerosis.

Backner Y, Petrou P, Glick-Shames H, Raz N, Zimmermann H, Jost R, Scheel M, Paul F, Karussis D, Levin N.

Front Neurol. 2019 May 3;10:455. doi: 10.3389/fneur.2019.00455. eCollection 2019.

Supplemental Content

Support Center